Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121207 | 0.88 | MRGPRX4 (0.52) | SLC6A2SLC6A3SLC6A4CSNK2A1ROCK2 | |
| SCHEMBL4367987 | 0.83 | ST14 (0.50) | SLC6A2SLC6A3SLC6A4CSNK2A1ROCK2 | |
| SCHEMBL757869 | 0.82 | SLC6A2 (0.49) | SLC6A2SLC6A3SLC6A4CSNK2A1ROCK2 | |
| SCHEMBL4369522 | 0.79 | CSNK2A1 (0.51) | SLC6A4CSNK2A1ROCK2ROCK1LOXL2 | |
| SCHEMBL20384450 | 0.78 | EPAS1 (0.51) | ROCK2ROCK1AKT1RPS6KA1LOXL2 | |
| SCHEMBL12239000 | 0.77 | ROCK2 (0.52) | SLC6A4CSNK2A1ROCK2ROCK1 | |
| SCHEMBL12238998 | 0.76 | ROCK2 (0.51) | SLC6A4CSNK2A1ROCK2ROCK1AKT1 | |
| SCHEMBL4370586 | 0.76 | HSPB1 (0.54) | ROCK2ROCK1LOXL2TRPA1 | |
| SCHEMBL15330147 | 0.72 | TRPA1 (0.48) | SLC6A2SLC6A3SLC6A4TRPA1 | |
| SCHEMBL921313 | 0.72 | ROCK2 (0.50) | SLC6A4ROCK2ROCK1AKT1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | SLC6A2 1647/4885SLC6A3 2382/4885SLC6A4 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.